T-CURX Acquires Germany’s Pantherna Therapeutics to Accelerate LNP-Based In Vivo CAR-T Therapy Development; United Immunity Also Enters In Vivo CAR-M Therapy for Solid Tumors and Fibrotic Diseases

HealthcareNOWradio.com Germany

Overview

T-CURX acquired Germany-based Pantherna Therapeutics, specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technology, aiming to accelerate in vivo CAR-T therapy development and clinical translation of its CAR-T strategy. Separately, United Immunity acquired multiple assets from Carisma Therapeutics and plans to develop in vivo CAR-M therapy for solid tumors and fibrotic diseases, utilizing a PEG-free pullulan-coated LNP delivery system. These movements highlight the evolution of cell and gene therapies driven by nanotechnology.

In Depth

Key Findings

Germany’s T-CURX has acquired Pantherna Therapeutics, a biotechnology company specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technology, aiming to accelerate the development of in vivo CAR-T therapies. Independently, United Immunity has acquired multiple assets from Carisma Therapeutics and plans to develop in vivo CAR-M therapies for solid tumors and fibrotic diseases, utilizing a PEG-free pullulan-coated LNP delivery system. These strategic moves demonstrate the synergistic integration of nanotechnology in the next generation of cell and gene therapies.

Technical / Clinical Details

T-CURX’s Acquisition of Pantherna Therapeutics: Pantherna Therapeutics possesses deep expertise in mRNA drug development, particularly in designing optimized mRNA sequences and efficient LNP delivery systems. By integrating this technology into its CAR-T platform, T-CURX aims to accelerate the development of in vivo CAR-T therapies, which induce CAR-T cells directly within the patient’s body. Traditional CAR-T therapy requires ex vivo cell processing, posing challenges of high cost and manufacturing complexity; the in vivo approach has the potential to overcome these hurdles, enhancing treatment simplicity and accessibility.

United Immunity’s Development of In Vivo CAR-M Therapy: The assets acquired by United Immunity from Carisma Therapeutics are presumed to include technologies and pipelines related to CAR macrophage (CAR-M) therapy. United Immunity plans to combine these with its proprietary PEG-free pullulan-coated LNP delivery system to develop in vivo CAR-M therapy for solid tumors and fibrotic diseases. The pullulan-coated LNP aims to mitigate immunogenicity and pharmacokinetic issues reported with existing LNPs by avoiding PEG (polyethylene glycol), striving for efficient gene delivery to macrophages. CAR-M cells are considered promising for treating solid tumors, a challenge for CAR-T therapy, due to their ability to infiltrate the solid tumor microenvironment and overcome immunosuppression.

Background & Context

While cell and gene therapies, especially CAR-T therapy, have achieved dramatic success in hematological cancers, challenges such as applicability to solid tumors, manufacturing complexity, high costs, and immunogenicity remain. Advances in LNP technology have paved the way for efficient in vivo delivery of mRNA and DNA, accelerating the development of next-generation cellular therapies (in vivo CAR-T/CAR-M). These strategic acquisitions and partnerships by major biotechnology companies underscore that nanotechnology is a critical key to expanding the frontiers of cell and gene therapy, offering treatment options for a broader range of diseases.

Strategic Significance & Outlook

The acquisition of Pantherna by T-CURX holds the potential to expedite the clinical development of in vivo CAR-T therapies and transform the landscape of cancer treatment. Meanwhile, United Immunity’s in vivo CAR-M therapy is expected to offer a new breakthrough in areas where previous immunotherapies have struggled, such as solid tumors and fibrosis. This convergence of nanotechnology and cell/gene therapy promises to improve the manufacturing efficiency of therapeutic agents, expand patient access, and mark a significant step towards realizing personalized medicine. Future clinical trial results will be key to elucidating the true potential of these innovative approaches.